Chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect.
- Resource Type
- Article
- Authors
- Lewis, Katharine L.; Cheah, Chan Y.
- Source
- British Journal of Haematology. Dec2023, Vol. 203 Issue 5, p701-703. 3p.
- Subject
- *MANTLE cell lymphoma
*CHIMERIC antigen receptors
*BRUTON tyrosine kinase
*CENTRAL nervous system
*T cells
- Language
- ISSN
- 0007-1048
This article discusses the use of chimeric antigen receptor (CAR) T-cell therapy for mantle cell lymphoma (MCL) patients with central nervous system (CNS) involvement. The study found that CAR-T-cell therapy had a high overall response rate (86% for CNS and 90% for systemic), but also had significant neurotoxicity that requires further investigation. Previous studies have shown that covalent Bruton's tyrosine kinase inhibitors (cBTKi) may be effective for CNS MCL, but most patients are already exposed to cBTKi at the time of CNS involvement. The article concludes that larger datasets are needed to fully understand the efficacy and toxicity of CAR-T-cell therapy for CNS MCL. [Extracted from the article]